To further investigate the mechanism of SGLT2 inhibitors in treating DCM, KEGG pathway enrichment of proteome and metabolome differences was performed in the EMPA and HG groups (Figures 5A,B). The gene discussed is SLC5A2; the disease is familial dilated cardiomyopathy.